 |
|
Targeted Treatment of Active Trachoma—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: Our prospective study examined the effect of azithromycin treatment on active trachoma and C trachomatis infection rates in an endemic area, with 2-year follow-up beyond the last treatment to determine risks of reemergence for both. We are aware of no similar studies despite documentation of reemergence 6 to 24 months following treatment.1 Dr Mabey and colleagues note 3 studies showing sustained infection reduction after mass treatment. However, 1 study found increasing infection prevalence from 2 to 12 months without further follow-up,2 another found infection reemergence in different villages from 2 to 24 months,3 and only 1 showed sustained reduction at 24 months.4
We used robust generalized estimating equation logistic and mixed effects models to perform longitudinal analysis of all individuals seen every 6 months to determine risk factors for reemergent infection. There were no differences among communes for active trachoma prevalence, demographics, ethnicity, socioeconomic status, or water access; . . . [Full Text of this Article]
Deborah Dean, MD, MPH
ddean@chori.org
Berna Atik, MD, MPH
Center for Immunobiology and Vaccine Development
Children's Hospital Oakland Research Institute
Oakland, Calif
Ton Thi Kim Thanh, MD;
Vu Quoc Luong, MD, PhD
National Institute of Ophthalmology
Ministry of Health
Stephan Lagree, PhD
Group Research in Technology Exchange
Hanoi, Vietnam
RELATED LETTERS
Targeted Treatment of Active Trachoma
, , , , , , , and
JAMA. ;297():588-588.
FULL TEXT
Targeted Treatment of Active Trachoma
and
JAMA. ;297():588-589.
FULL TEXT
|
